NCT04964908

Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia

CREEK is a Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Pathway and Resource Utilization for Patients With Chronic Lymphocytic Leukemia in International Region.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,088 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions

Detailed description

CREEK is a retrospective, observational, registry-based study including patients with an incidental diagnosis of CLL and started treatment (1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016 and 12 months before data collection as identified from the patient records (from participating hospitals across the GCC States and the International region countries) with at least 12 months of follow-up, after starting on treatment. Moreover, the study will include a pilot cohort in the GCC as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive CLL patient

Conditions

• Chronic Lymphocytic Leukemia

Timeline

• Start date: 2021-12-03
• Primary completion: 2023-08-31
• Completion: 2023-08-31
• First posted: 2021-07-16
• Last updated: 2024-02-20

Locations

52 sites across 17 countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Egypt, India, Kuwait, Malaysia, Mexico, Panama, Saudi Arabia, Singapore, Taiwan, Turkey (Türkiye), United Arab Emirates